ArticleFrontiers in endocrinology2025
Comprehensive bioinformatics and
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Baicalein attenuates extracellular matrix remodeling via FN1 in diabetic kidney disease: a multi-omics, machine-learning and mesangial-cell rescue study.Frontiers in pharmacology · 2026Article
- COL1A2 and APOLD1 Define a Dual-Axis Molecular Framework for Diabetic Nephropathy-Retinopathy Comorbidity: An Integrative Multiomics and Machine Learning Study in Mouse Models.International journal of medical sciences · 2026Article
- Inflammatory mechanisms in diabetic nephropathy: emerging insights and targeted therapeutics.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy is a leading cause of end-stage renal disease worldwide, characterized by progressive glomerulosclerosis, chronic inflammation, and extracellular matrix (ECM) accumulation. Despite advances in clinical management, the underlying molecular mechanisms remain incompletely understood, and reliable biomarkers for early diagnosis and targeted therapy are still lacking. Methods: To identify candidate molecular genes associated with DN, we conducted an integrative bioinformatics analysis combining transcriptomic profiling, weighted gene co-expression network analysis, protein-protein interaction network construction, and machine learning-based feature selection. The biological relevance of candidate genes was validated using human renal biopsy specimens and two diabetic mouse models. Gene set enrichment analysis was performed to uncover associated functional pathways. Results: Four genes-COL1A2, CD163, FN1, and CCL2-were consistently upregulated in both human and murine DN samples. These genes are closely associated with immune activation, ECM remodeling, and chronic inflammation. GSEA revealed their significant enrichment in pathways such as NOD-like receptor signaling, ECM-receptor interaction, and T/B cell receptor signaling, highlighting their potential roles in DN pathogenesis. Experimental validation confirmed elevated expression of these genes at both mRNA and protein levels. Conclusion: Our study identifies COL1A2, CD163, FN1, and CCL2 as key molecular signatures involved in the immunoinflammatory and fibrotic progression of diabetic nephropathy. These genes hold promise as potential biomarkers and therapeutic targets, offering novel insights into the molecular mechanisms and clinical management of DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.